[PR] Preclinical Combination Studies of HBV Therapeutic Candidates at EASL 2018 | ABUS Message Board Posts

Arbutus Biopharma

  ABUS website

ABUS   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  34264 of 34745  at  4/12/2018 3:36:28 PM  by

egomaniakos

The following message was updated on 4/12/2018 3:37:31 PM.

 In response to msg 34261 by  liuyiiv
view thread

Re: [PR] Preclinical Combination Studies of HBV Therapeutic Candidates at EASL 2018

 
The thing that struck me most in the detailed presentations is that sc appears to be 1 RNAi targetting ligand.
So iv might retain depth potency and coverage advantages. I see a dual RNAi application.  The other agents are looking good too.
ego
 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 1     Views: 274
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board






About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...